---
title: "Beyond the Image"
subtitle: "Addressing Disparities in \n \n Uterine Fibroid Embolization"
title-slide-attributes:
  data-background-image: images/title-invert.png
  data-background-size: auto 100%
  data-background-opacity: "0.5"
  data-background-position: right 0% bottom 45%
format:
  clean-revealjs:
    transition: fade
    self-contained: true
    preview-links: false
    slide-number: c/t
    logo: images/mcw-logo.svg
    footer: |
      [Back to Site](https://mkabangu.github.io/mirindikabangu)
author:
    name: Mirindi Kabangu, BS
    orcid: 0000-0002-4605-9089
    email: mkabangu@iu.edu
    affiliations: Indiana University School of Medicine
date: last-modified
execute: 
  cache: true
---

## Overview

::: incremental
-   Case

-   Anatomy

-   Literature
:::

## HISTORY {auto-animate="true"}

::: {.fragment .fade-in-then-semi-out}
42-year-old woman
:::

::: {.fragment .fade-in-then-semi-out}
Hypertension, dyslipidemia, diabetes
:::

::: {.fragment .fade-in-then-semi-out}
Heavy menstrual bleeding, pelvic pressure, fatigue
:::

::: {.fragment .fade-in-then-semi-out}
Enlarged uterus (\~14 weeks size)
:::

::: {.fragment .fade-in}
What's your differential?
:::

##  {auto-animate="true"}

::: {style="margin-top: 10px; font-size: 1em; color: red;"}
Differential?
:::

::: incremental
- Endometrial Cancer
- Adenomyosis
- Leiomyoma
- Leiomyosarcoma
:::

## What is Your First Step in Imaging?

## ACR Criteria

[![](images/acr-ac-aub-v1.png){fig-align="center"}](https://acsearch.acr.org/docs/69458/Narrative/)

## Ultrasound {background-color="black" auto-animate="true" auto-animate-easing="ease-in-out"}

:::: columns
::: {.column .fragment width="50%"}
![](images/lm-us-sag.png)
:::
::::

::: aside
Doubilet PM, et al. Atlas of Ultrasound in Obstetrics and Gynecology: A Multimedia Reference, 3e.
:::

## Ultrasound {background-color="black" auto-animate="true" auto-animate-easing="ease-in-out"}

::::: columns
::: {.column width="25%"}
![](images/lm-us-sag.png)
:::

::: {.column width="50%"}
![](images/lm-us-cor.png)
:::
:::::

::: aside
Doubilet PM, et al. Atlas of Ultrasound in Obstetrics and Gynecology: A Multimedia Reference, 3e.
:::

## Ultrasound {background-color="black" auto-animate="true" auto-animate-easing="ease-in-out"}

:::::: columns
::: {.column width="25%"}
![](images/lm-us-sag.png)
:::

::: {.column width="25%"}
![](images/lm-us-cor.png)
:::

::: {.column width="50%"}
![](images/lm-us-dop.png)
:::
::::::

::: aside
Doubilet PM, et al. Atlas of Ultrasound in Obstetrics and Gynecology: A Multimedia Reference, 3e.
:::

## Ultrasound {background-color="black" auto-animate="true" auto-animate-easing="ease-in-out"}

:::::: columns
::: {.column width="25%"}
![](images/lm-us-sag.png)
:::

::: {.column width="25%"}
![](images/lm-us-cor.png)
:::

::: {.column width="25%"}
![](images/lm-us-dop.png)
:::
::::::

Diagnosis?

. . .

What kind?

::: aside
Doubilet PM, et al. Atlas of Ultrasound in Obstetrics and Gynecology: A Multimedia Reference, 3e.
:::

## Uterine fibroid types {auto-animate="true" auto-animate-easing="ease-in-out"}

:::: columns
::: {.column .fragment width="60%"}
![](images/lm-mayo-types.png){alt="https://www.mayoclinic.org/diseases-conditions/uterine-fibroids/symptoms-causes/"}
:::
::::

::: aside
https://www.mayoclinic.org/diseases-conditions/uterine-fibroids/symptoms-causes/
:::

## Uterine fibroid types {auto-animate="true" auto-animate-easing="ease-in-out"}

::::: columns
::: {.column width="40%"}
![](images/lm-mayo-types.png){alt="https://www.mayoclinic.org/diseases-conditions/uterine-fibroids/symptoms-causes/"}
:::

::: {.column .incremental width="60%"}
#### FIGO Classification System

##### Submucosal Group

-   Type 0: pedunculated intracavitary

-   Type 1: \<50% intramural

-   Type 2: ≥50% intramural
:::
:::::

::: aside
https://www.mayoclinic.org/diseases-conditions/uterine-fibroids/symptoms-causes/
:::

## Uterine fibroid types {auto-animate="true" auto-animate-easing="ease-in-out"}

::::: columns
::: {.column width="40%"}
![](images/lm-mayo-types.png){alt="https://www.mayoclinic.org/diseases-conditions/uterine-fibroids/symptoms-causes/"}
:::

::: {.column .incremental width="60%"}
#### FIGO Classification System

##### Other Group

-   Type 3: 100% intramural; contacts endometrium

-   Type 4: intramural

-   Type 5: subserosal ≥50% intramural

-   Type 6: subserosal \<50% intramural

-   Type 7: subserosal pedunculated

-   Type 8: other, e.g. cervical, parasitic
:::
:::::

::: aside
https://www.mayoclinic.org/diseases-conditions/uterine-fibroids/symptoms-causes/
:::

## Ultrasound {background-color="black" auto-animate="true" auto-animate-easing="ease-in-out"}

:::: columns
::: {.column .fragment width="50%"}
![](images/lm-submucosal-us.jpeg)
:::
::::

::: aside
Doubilet PM, et al. Atlas of Ultrasound in Obstetrics and Gynecology: A Multimedia Reference, 3e.
:::

## Ultrasound {background-color="black" auto-animate="true" auto-animate-easing="ease-in-out"}

::::: columns
::: {.column width="25%"}
![](images/lm-submucosal-us.jpeg)
:::

::: {.column width="50%"}
![](images/lm-subserosal-us.png)
:::
:::::

::: aside
Doubilet PM, et al. Atlas of Ultrasound in Obstetrics and Gynecology: A Multimedia Reference, 3e.
:::

## Ultrasound {background-color="black" auto-animate="true" auto-animate-easing="ease-in-out"}

:::::: columns
::: {.column width="25%"}
![](images/lm-submucosal-us.jpeg)
:::

::: {.column width="25%"}
![](images/lm-subserosal-us.png)
:::

::: {.column width="50%"}
![](images/lm-pedunculated-us.png)
:::
::::::

::: aside
Doubilet PM, et al. Atlas of Ultrasound in Obstetrics and Gynecology: A Multimedia Reference, 3e.
:::

## Ultrasound {background-color="black" auto-animate="true" auto-animate-easing="ease-in-out"}

:::::: columns
::: {.column width="25%"}
![](images/lm-submucosal-us.jpeg)
:::

::: {.column width="25%"}
![](images/lm-subserosal-us.png)
:::

::: {.column width="25%"}
![](images/lm-pedunculated-us.png)
:::
::::::

What next?

::: aside
Doubilet PM, et al. Atlas of Ultrasound in Obstetrics and Gynecology: A Multimedia Reference, 3e.
:::

## ACR Criteria

[![](images/acr-ac-aub-v2.png){fig-align="center"}](https://acsearch.acr.org/docs/69458/Narrative/)

## MRI {background-color="black" auto-animate="true" auto-animate-easing="ease-in-out"}

:::: columns
::: {.column .fragment width="40%"}
![](images/lm-t2-saggital.jpg)
:::
::::

::: aside
Case courtesy of Hani M. Al Salam, Radiopaedia.org, rID: 12507
:::

## MRI {background-color="black" auto-animate="true" auto-animate-easing="ease-in-out"}

::::: columns
::: {.column width="40%"}
![](images/lm-t2-saggital.jpg)
:::

::: {.column width="40%"}
![](images/lm-t1-pc-saggital.jpg)
:::
:::::

::: aside
Case courtesy of Hani M. Al Salam, Radiopaedia.org, rID: 12507
:::

## Ultrasound {background-color="black" auto-animate="true" auto-animate-easing="ease-in-out"}

:::: columns
::: {.column .fragment width="50%"}
![](images/pregnant-t2-axial.jpg)
:::
::::

::: aside
Case courtesy of Roberto Schubert, Radiopaedia.org, rID: 16726
:::

## Cystic Degeneration {background-color="black" auto-animate="true" auto-animate-easing="ease-in-out"}

::::: columns
::: {.column width="25%"}
![](images/pregnant-t2-axial.jpg)
:::

::: {.column width="50%"}
![](images/pregnant-t1-axial.jpg)
:::
:::::

::: aside
Case courtesy of Roberto Schubert, Radiopaedia.org, rID: 16726
:::

## Cystic Degeneration {background-color="black" auto-animate="true" auto-animate-easing="ease-in-out"}

:::::: columns
::: {.column width="25%"}
![](images/pregnant-t2-axial.jpg)
:::

::: {.column width="25%"}
![](images/pregnant-t1-axial.jpg)
:::

::: {.column width="50%"}
![](images/pregnant-t2-coronal.jpg)
:::
::::::

::: aside
Case courtesy of Roberto Schubert, Radiopaedia.org, rID: 16726
:::

## What next?

### Treatment Modalities & Selection Criteria 

::: {.fragment}
**Medical Management**

-   **First-line** for most patients

-   **Options**: NSAIDs, tranexamic acid, combined oral contraceptives, progestins, LNG-IUS

-   **Guideline**: ACOG recommends starting with medical therapy for symptomatic management
:::

## What next?

### Treatment Modalities & Selection Criteria 

**Myomectomy**

-   **Gold standard** for fertility preservation

-   **Approaches**: Hysteroscopic (submucosal), laparoscopic (selected cases), abdominal (complex)

-   **Consider**: Fibroid size, number, location, and surgical expertise


## What next?

### Treatment Modalities & Selection Criteria 

**Hysterectomy**

-   **Definitive treatment** for completed childbearing

-   **Consider**: Failed medical/conservative treatments, large symptomatic fibroids

-   **Approach**: Minimally invasive preferred when feasible


## What next?

### Treatment Modalities & Selection Criteria 


**Uterine Artery Embolization (UAE)**

-   **Ideal candidate**: Women who desire uterine preservation but not future pregnancy

-   **ACR Appropriateness**: Usually appropriate for symptomatic fibroids

-   **Evidence**: 85-95% symptom improvement, equivalent to myomectomy at 2 years

## Anatomy {background-color="black"}

::: r-stack
![](images/iliac-dsa-unlabeled.jpg){.fragment width="600"}

![](images/iliac-dsa-common-iliac.jpg){.fragment width="600"}

![](images/iliac-dsa-iliolumbar.jpg){.fragment width="600"}

![](images/iliac-dsa-superior-gluteal.jpg){.fragment width="600"}

![](images/iliac-dsa-middle-rectal.jpg){.fragment width="600"}
:::

::: aside
Case courtesy of Craig Hacking, Radiopaedia.org, rID: 156512
:::

## Anatomy Mnemonic {.smaller}

::: fragment
I Love Going Places In My Very Own Underwear!
:::

::: incremental
-   **I**: iliolumbar artery

-   **L**: lateral sacral artery

-   **G**: gluteal (superior and inferior) arteries

-   **P**: (internal) pudendal artery

-   **I**: inferior vesical (vaginal in females) artery.

-   **M**: middle rectal artery

-   **V**: vaginal artery (females only)

-   **O**: obturator artery

-   **U**: umbilical artery and uterine artery (females only)
:::

## Evidence

:::: fragment
::: {.column width="100%"}
![](images/jama-ufe.png)
:::
::::

## Patient Characteristics {.scrollable}

::: {.column width="100%"}
![](images/jama-demo.svg)
:::

## Treatment Distribution by Location

::: {.column width="100%"}
![](images/jama-loc-dist.png)
:::

## Treatment Distribution by Race {.scrollable}

::: {.column width="100%"}
![](images/jama-odds.svg)
:::

## Shared Decision-Making Essentials {.incremental}

### Key Discussion Points:

-   Reproductive plans and timing

-   Symptom severity and impact on quality of life

-   Treatment risks and recovery expectations

-   Long-term outcomes and recurrence risks

-   Personal values and preferences

## Shared Decision-Making Essentials {.incremental}

### Key Discussion Points:

-   ACOG Practice Bulletin #228 (2021)

-   ACR Appropriateness Criteria®

-   SIR Guidelines for UAE

-   ESHRE Guidelines on Fibroid Management
